+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Programmed Cell Death Protein"

Malignant Pleural Mesothelioma- Pipeline Insight, 2025 - Product Thumbnail Image

Malignant Pleural Mesothelioma- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Advanced Urothelial Carcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Advanced Urothelial Carcinoma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Advanced Gastric Carcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Advanced Gastric Carcinoma - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 80 Pages
  • Global
From
Thyroid Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Thyroid Cancer - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 180 Pages
  • Global
From
Biliary Tumor - Pipeline Insight, 2025 - Product Thumbnail Image

Biliary Tumor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 180 Pages
  • Global
From
Metastatic Liver Cancer- Pipeline Insight, 2025 - Product Thumbnail Image

Metastatic Liver Cancer- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Nasopharyngeal Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Nasopharyngeal Cancer - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
RET (Ret Proto-Oncogene) Protein Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

RET (Ret Proto-Oncogene) Protein Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
TIM-3 Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

TIM-3 Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Metastatic Merkel Cell Carcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Metastatic Merkel Cell Carcinoma - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 90 Pages
  • Global
From
Gallbladder Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Gallbladder Cancer - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 50 Pages
  • Global
From
Chemotherapy Induced Febrile Neutropenia - Pipeline Insight, 2025 - Product Thumbnail Image

Chemotherapy Induced Febrile Neutropenia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Clear Cell Sarcoma - Pipeline Insight, 2025 - Product Thumbnail Image

Clear Cell Sarcoma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Anaplastic Thyroid Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Anaplastic Thyroid Cancer - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
From
Checkpoint Inhibitor Refractory Cancer Market Report 2025 - Product Thumbnail Image

Checkpoint Inhibitor Refractory Cancer Market Report 2025

  • Report
  • September 2025
  • 250 Pages
  • Global
From
Head and Neck Cancer Therapeutics Market Report 2025 - Product Thumbnail Image

Head and Neck Cancer Therapeutics Market Report 2025

  • Report
  • September 2025
  • 250 Pages
  • Global
From
Gastric Cancer Drugs Market Report 2025 - Product Thumbnail Image

Gastric Cancer Drugs Market Report 2025

  • Report
  • September 2025
  • 250 Pages
  • Global
From
From
Loading Indicator

Programmed Cell Death Protein (PDP) is a type of protein that plays a role in the regulation of cell death in the body. It is a key component of the body's natural defense against cancer, as it helps to prevent the growth and spread of cancerous cells. In oncology drugs, PDP is used to target and destroy cancer cells, while leaving healthy cells unharmed. PDP is also used to reduce the side effects of chemotherapy and radiation therapy, as well as to reduce the risk of recurrence of cancer. PDP is also used to reduce the risk of metastasis, or the spread of cancer to other parts of the body. PDP is a rapidly growing market, with many companies developing and marketing PDP-based drugs. Some of these companies include Merck, Bristol-Myers Squibb, AstraZeneca, Novartis, and Pfizer. Show Less Read more